MedPath

The Effects of Systemic Isotretinoin Treatment on Adrenal Steroid and Sex Hormones Level in Severe Acne Vulgaris

Recruiting
Conditions
Acne Vulgaris
Interventions
Diagnostic Test: Hormone
Registration Number
NCT05903716
Lead Sponsor
Marmara University
Brief Summary

Acne vulgaris is a chronic inflammatory skin disease involving the pilosebaceous unit, affecting approximately 95% of adolescents and young adults.

Follicular hyperkeratinization, increased sebum production, androgen hormones and inflammation play a role in the pathogenesis of acne. Androgens (Testosterone, DHEA-S and DHT) play a role in the development of acne, hypertrophy of the sebaceous glands and increased sebum production. Androgen receptors are located in the basal layer of the sebaceous glands keratinocytes and they are located in the outer sheath of the hair follicle. These receptors are responsible for the proliferative action of keratinocytes.

The relationship between androgen hormones and acne in women and prepubertal children is well known. Many studies have shown a strong association between acne and hyperandrogenism in women.

Systemic isotretinoin therapy can be used in patients with severe acne vulgaris who do not respond to topical and oral antibiotic treatments.

In recent studies, it has been shown that systemic isotretinoin used in acne treatment changes many hormones such as GnRH, FSH, LH, Estrogen, Progesterone, Testosterone, TSH, T4 and Prolactin and causes side effects such as menstrual irregularity and hirsutism.

However, data on the effect of oral isotretinoin on adrenal and sex hormones are contradictory.

In this study, it was aimed to evaluate the effect of oral isotretinoin on adrenal steroid and sex hormone levels and to compare it with a healthy control.

Isotretinoin treatment is started in acne vulgaris patients at a dose of 0.5-0.8mg/kg/day. The total cumulative dose is 120 mg/kg.

At baseline and at the 3rd month of isotretinoin treatment, 17-OH Progesterone, DHEA, DHEAS, Androstenedione, Aldosterone, Testosterone, Dihydrotestosterone, Estradiol, 17-OH Pregnenolone, Androsterone, Cortisol, Corticosterone, 11-Degesterone, 21, -Deoxycortisol, Pregnenolone, 11-Deoxycorticostreone hormones will be evaluated with LCMS/MS technique.

In addition, the FSH, LH, Prolactin, Estrogen, Testosterone, free testosterone, DHEA-s, SHBG, TSH, T4 hormone levels of the patients will be evaluated by ELISA method.

In the baseline 2nd, 3rd, 4th and 6th months of the treatment and 3 months after the treatment, the patients' height, weight, body mass index measurements, VAS scoring of patient treatment satisfaction, Global Acne Severity Score, Acne Quality of Life Score, and Modified Ferriman Gallwey Score for hirsutism will be recorded.

The side effects of isotretinoin such as menstrual irregularity, increased hair growth, and cheilitis, dryness of the oral mucosa, skin dryness, dermatitis seen in patients during treatment will be recorded.

\*Hormone tests were performed on 2th and 3rd days of menstruation

Detailed Description

Not available

Recruitment & Eligibility

Status
RECRUITING
Sex
Female
Target Recruitment
40
Inclusion Criteria
  • Severe to moderate acne vulgaris
  • 14 - 20 Years old
  • Female patients
Exclusion Criteria
  • Male patients
  • Patients who received vitamin A or hormone therapy in the last 3 months
  • Those with adrenal, thyroid, pituitary gland disease
  • Those with psychiatric disorders
  • History of drug use that causes acneiform eruption (eg, corticosteroids...)
  • Acne conglobata and acne fulminans

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
Severe acne vulgarisHormone40 female patients aged 14-20 years, who were diagnosed with severe to moderate acne bulgaris and will be treated with isotretinoin.
Healthy controlHormone40 female patients aged 14-20 years
Severe acne vulgarisIsotretinoin40 female patients aged 14-20 years, who were diagnosed with severe to moderate acne bulgaris and will be treated with isotretinoin.
Primary Outcome Measures
NameTimeMethod
DHEA(LCMS) Level3rd month of isotretinoin treatment

Evaluation DHEA(LCMS) levels after 3 month of isotretinoin treatment

T4 Level3rd month of isotretinoin treatment

Evaluation T4 levels after 3 month of isotretinoin treatment

17-OH Progesteroone Level3rd month of isotretinoin treatment

Evaluation 17-OH Progesteroone after 3 month of isotretinoin treatment

DHEA-S(LCMS) Level3rd month of isotretinoin treatment

Evaluation DHEAS(LCMS) levels after 3 month of isotretinoin treatment

Testosterone(LCMS) Level3rd month of isotretinoin treatment

Evaluation Testosterone(LCMS) levels after 3 month of isotretinoin treatment

Estrogen Level3rd month of isotretinoin treatment

Evaluation Estrogen levels after 3 month of isotretinoin treatment

DHEA-s Level3rd month of isotretinoin treatment

Evaluation DHEA-s levels after 3 month of isotretinoin treatment

Androstenedione Level3rd month of isotretinoin treatment

Evaluation Androstenedione levels after 3 month of isotretinoin treatment

FSH Level3rd month of isotretinoin treatment

Evaluation FSH levels in after 3 month of isotretinoin treatment

Testosterone Level3rd month of isotretinoin treatment

Evaluation Testosterone levels after 3 month of isotretinoin treatment

LH Level3rd month of isotretinoin treatment

Evaluation LH levels after 3 month of isotretinoin treatment

Prolactin Level3rd month of isotretinoin treatment

Evaluation Prolactin levels after 3 month of isotretinoin treatment

TSH Level3rd month of isotretinoin treatment

Evaluation TSH levels iafter 3 month of isotretinoin treatment

Androsterone Level3rd month of isotretinoin treatment

Evaluation Androsterone levels after 3 month of isotretinoin treatment

21-Deoxycortisololone Level3rd month of isotretinoin treatment

Evaluation 21-Deoxycortisololone levels after 3 month of isotretinoin treatment

Free-Testosterone Level3rd month of isotretinoin treatment

Evaluation Free-Testosterone levels after 3 month of isotretinoin treatment

SHBG Level3rd month of isotretinoin treatment

Evaluation SHBG levels after 3 month of isotretinoin treatment

Corticosterone Level3rd month of isotretinoin treatment

Evaluation Corticosterone after 3 month of isotretinoin treatment

Aldosterone Level3rd month of isotretinoin treatment

Evaluation Aldosterone levels after 3 month of isotretinoin treatment

Dihydrotestosterone Level3rd month of isotretinoin treatment

Evaluation Dihydrotestosterone levels after 3 month of isotretinoin treatment

Cortisol Level3rd month of isotretinoin treatment

Evaluation Cortisol levels after 3 month of isotretinoin treatment

Estradiol Level3rd month of isotretinoin treatment

Evaluation Estradiol levels after 3 month of isotretinoin treatment

17-OH Pregnenolone Level3rd month of isotretinoin treatment

Evaluation 17-OH Pregnenolone levels after 3 month of isotretinoin treatment

11-Deoxycortisol Level3rd month of isotretinoin treatment

Evaluation 11-Deoxycortisol levels after 3 month of isotretinoin treatment

Progesterone(LCMS) Level3rd month of isotretinoin treatment

Evaluation Progesterone(LCMS) levels after 3 month of isotretinoin treatment

11-Deoxycortisolone Level3rd month of isotretinoin treatment

Evaluation 11-Deoxycortisolone levels after 3 month of isotretinoin treatment

Pregnenolone Level3rd month of isotretinoin treatment

Evaluation Pregnenolone levels after 3 month of isotretinoin treatment

Secondary Outcome Measures
NameTimeMethod
Relationship between Menstrual irregularity and hormone levels3rd month of isotretinoin treatment

Evaluation of the relationship between menstrual irregularity and changes in hormone levels

Comparison of hormone levels in acne vulgaris patients and healthy groupBaseline

Comparison of all hormone levels in acne vulgaris patients and healthy group

Menstrual İrregularity2. 4. 6. months and 3 month after treatment

Evaluation of side effects such as menstrual irregularity that can be seen due to isotretinoin

Trial Locations

Locations (1)

Marmara University School of Medicine,Department of Dermatology.

🇹🇷

Istanbul, Turkey

© Copyright 2025. All Rights Reserved by MedPath